Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 11/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28688720 | 1.00 | OGA (0.60) | OGANPC1RAB9AKMT2AROCK2 | |
| SCHEMBL26199251 | 1.00 | OGA (0.60) | OGANPC1RAB9AKMT2AROCK2 | |
| SCHEMBL25168553 | 0.87 | OGA (0.58) | OGAGPR119PARP1 | |
| SCHEMBL25168554 | 0.87 | OGA (0.58) | OGAGPR119PARP1 | |
| SCHEMBL25171545 | 0.79 | SORD (0.52) | OGA | |
| SCHEMBL30179830 | 0.79 | SORD (0.52) | OGA | |
| SCHEMBL25171542 | 0.79 | SORD (0.52) | OGA | |
| SCHEMBL30179821 | 0.76 | OGA (0.45) | OGA | |
| SCHEMBL25168525 | 0.76 | OGA (0.45) | OGA | |
| SCHEMBL25168524 | 0.76 | OGA (0.45) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4177247-A1 | HETEROCYCLIC IMMUNOMODULATOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271933-A1 | HETEROCYCLIC IMMUNOMODULATOR | IL2, ICOS, IL5 | OGA 3260/4885NPC1 1237/4885RAB9A 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.